Introduction

Over the next 5 years, key products across the major infectious disease sectors are set to face patent expiry. With generics manufacturers lining up to produce cheaper equivalent products, companies will face significant challenges to maintain franchise sales. This brief will analyze the impact of such patent expiries in the antibacterial, HIV, herpes and fungal infection fields. 

Scope

Detailed analysis of forthcoming patent expiries in the antibacterial, HIV, antifungal and herpes markets 

Contrasting generic success in the HIV markets of the developed and developing world 

A number of case studies and past examples are used to illustrate successful defense strategies across the infectious disease therapy area 

A number of market leading drugs, that have or are about to lose patent, are analyzed, including Augmentin, Diflucan and Zovirax 

Report Highlights

The antibacterial and antifungal markets are the more attractive for generics manufacturers, with relatively easy market penetration and a high likelihood of success. 

The HIV market has yet to experience patent expiry. However, the import of generics into the developing world is widespread, creating a ‘two-tiered’ generics market. 

Generic defense strategies, while limited in scope, have been proven to restrict the impact of generic competition and can be employed in all markets to protect sales. 

Reasons to Purchase

Quantify the different impacts of generic incursion across the key infectious disease markets 

Identify key defense strategies used across infectious disease sectors to maintain sales following patent expiry 

Understand why some infectious disease markets are vulnerable to generic competition while others are not 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a209